Healthcare / BiotechnologyNasdaqGS
$16.94
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-101.4M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
4/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$918M
P/E
N/A
•EV/EBITDA
N/A
•ROE
423.6%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-696.0M · FCF $-143.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-696.0M | $-696.0M | $-116.9M | $-117.9M | $-92.1M | $-68.9M | $-43.3M |
| EPS | -70.50 | -70.50 | -34.03 | -1.75 | -2.33 | -2.10 | — |
| Cash Flow | |||||||
| Free Cash Flow | $-143.7M | $-143.7M | $-99.9M | $-101.4M | $-93.6M | $-73.0M | $-40.5M |
| Returns | |||||||
| ROE | 423.6% | 423.6% | -120.9% | -78.2% | -36.7% | -31.9% | 73.4% |
| Growth & Yield | |||||||
| EPS Growth | -107.2% | -107.2% | -1844.6% | 24.9% | -11.0% | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.